PubMed Health⌕ Search

Biomedical subjects

V A Orlov

Publications and source records attributed to V A Orlov.

At least 19 recordsLinked to original sources
PubMed2005

[Therapeutic efficacy of mildronate in pulmonary diseases].

Immuno-corrective action of the medication has been proved by analyzing Mildronate administration in 64 patients with bronchial asthma and secondary immunodeficiency. Stimulation of sell component and inhibition of humoral component of the immunity system, improvement of central hemodynamics and normalization of the hemopoiesis system to some extent have been observed in the patients. The patients with chronic catarrhal obstructive bronchitis in acute stage and patients with infection-allergic bronchial asthma showed decrease in bronchial obstruction under the treatment with the medication.

Adjuvants, Immunologic↗
PubMed2005

[Therapy of urinary tract infections in patients with diabetes mellitus].

Clinical and microbiological efficacy of Cifran OD (Ranbaxy, India), a formulation with prolonged action and extended release of ciprofloxacin was studied in 22 patients with bacteriuria and lingering diabetes mellitus. Ciprofloxacin was used in doses of 500 or 1000 mg orally once a day depending on the severity of the disease singns for 2-3 weeks as etiotropic therapy and only in 2 cases with severe pyelonephritis it was used intravenously drop-wise and orally simultaneously. Twenty eight microbial strains isolated from urea of the patients were tested. The main species of the isolates belonged to the family Enterobacteriaceae. Twenty five isolates (89.3%) were susceptible to ciprofloxacin and 3 isolates (10.7%) were resistant. The clinical efficacy of ciprofloxacin was 90.9%.

Administration, Oral↗
PubMed2004

[Therapy of bronchopulmonary infection in smokers].

The efficacy and safety of Cifran OD, a new dosage form of ciprofloxacin with prolonged action were studied in the treatment of patients with bronchopulmonary infection (n=23). The drug was used orally in a dose of 1 g once a day. The patients were divided into 2 groups: group 1 included patients with aggravation of chronic bronchitis and group 2 included patients with bacterial pneumonia. The recovery was stated in 77.7% of the patients in group 1, the other 26.3% of the patients showed clinical improvement. In the patients with pneumonia (group 2) the recovery was recorded in 100% of the cases. No significant side effects were observed.

Adult↗
PubMed2004

[Practical prevention and treatment of cardiovascular diseases in patients with diabetes mellitus type 2 in an endocrinological department].

AIM: To analyse retrospectively quality of medical correction of modified risk factors (RF) and treatment of cardiovascular diseases (CVD) in patients with diabetes mellitus type (DM) 2 admitted to specialized endocrinological departments. MATERIAL AND METHODS: Analysis of medication policy of CVD RF was made retrospectively for 250 patients treated in endocrinological departments of Moscow hospital in 2003. RESULTS: Arterial hypertension, coronary heart disease were diagnosed in 93.2 and 87.2% examinees. History of myocardial infarction and brain stroke was in 8.4 and 6% patients. Statins were prescribed in 2.4% cases. Examination for dyslipidemia was not satisfactory. ACE inhibitors were prescribed in 71.2% patients. Aspirin was prescribed (18%) primarily by the cardiologist. CONCLUSION: Quality of medical prophylaxis of CVD RF in DM type 2 patients in the departments does not satisfy modern clinical recommendations.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2002

[Current possibilities and perspectives of the combined treatment of patients with severe bronchopulmonary diseases].

Complex treatment with ceftriaxone (or ceftazidime) and intravenous immunoglobulin G (Biaven V. I.) was performed at 21 patients with severe pneumonia and tracheobronchitis complicated by immunedeficient status (myasthenia, diabetes mellitus etc). The results of the treatment proves strong tendency to normalization of the immune system (ceruloplasmin level, CIC, catalase, immunoglobulins) along with clinical signs regression.

Aged↗
PubMed2001

[Clinico-laboratory assessment of oframax (cefriaxone) in the treatment of infectious-inflammatory diseases].

AIM: To try efficacy and safety of ophramax (cephtriaxon) made in India ("Ranbaxy") in infectious-inflammatory diseases treated in a general hospital. MATERIAL AND METHODS: Ophramax was given in a dose 1 to 4 g/day to 23 patients with pneumonia, chronic bronchitis, soft tissue infection, enterocolitis, etc. Therapeutic effect was examined with bacteriological identification of the infective agents, antibioticograms, agar diffusion test. RESULTS: High sensitivity of pathogens to ophramax was observed in bronchopulmonary diseases (90.7%). In other infections sensitivity of the pathogens was 59.3%. Enterococci were the only highly resistant pathogens (40.5%). Ophramax remains in the body in sufficiently high concentrations for 24 hours. This attributes to good therapeutic effect. CONCLUSION: Clinico-microbiological and pharmacokinetic findings show that ophramax can be used as a basic drug for treatment of different infectious-inflammatory diseases. Once-a-day regimen is a great advantage of ophramax.

Adult↗
PubMed1999

[Clinical, bactericidal and pharmacological evaluation of the effects of netromycin].

AIM: To analyze clinical, bactericidal effectiveness and pharmacokinetics of wide-spectrum antibiotic netromycin (NM). MATERIALS AND METHODS: The trial entered 29 patients: 21 with bronchopulmonary diseases (pneumonia and chronic bronchitis), 5 with exacerbation of chronic pyelonephritis, 2 with infectious endocarditis and 1 with peritonsillar abscess. RESULTS: Microbiologically, most of the agents (80.36%) showed sensitivity to NM. Pharmacologically, NM persisted long in blood serum and sputum irrespective of the administration mode. Positive clinical dynamics after NM treatment was achieved in all the patients but one who had a peritonsillar abscess. CONCLUSION: NM is highly active against both gram-positive and gram-negative flora. Side effects are minimal.

Adult↗
PubMed1998

Valsartan in heart failure patients previously untreated with an ACE inhibitor.

OBJECTIVE: To evaluate the effect on cardiac hemodynamic parameters of valsartan in patients with chronic stable congestive heart failure previously untreated with ACE inhibitors. METHODS: After a 2 to 4 week run-in period, 116 adult outpatients were randomized to receive valsartan 40, 80 or 160 mg twice daily, the ACE inhibitor lisinopril 5/10 mg once daily, or placebo. At baseline and after 28 days of treatment, cardiac hemodynamic parameters were measured. Tolerability was assessed by adverse events and by any changes in systolic or diastolic blood pressure, body weight, heart rate, and routine laboratory parameters. RESULTS: For the 12 hour time point (trough), all doses of valsartan reduced mean pulmonary capillary wedge pressure (statistically significant for valsartan 40 mg and 160 mg), decreased systemic vascular resistance (statistically significant for all three valsartan doses and for lisinopril at peak and trough), and increased cardiac output (statistically significant for all three valsartan doses at peak, and for 80 and 160 mg at trough). There were no clinically relevant effects on any safety parameters. CONCLUSIONS: Valsartan has beneficial effects on cardiac hemodynamics, and is generally well tolerated in patients with congestive heart failure not taking ACE inhibitors.

Adult↗
PubMed1992

[The clinico-laboratory dynamics in the reaferon treatment of glomerulonephritis patients with the nephrotic syndrome].

Overall 40 chronic glomerulonephritis patients with nephrotic syndrome were treated by reaferon. All the patients underwent clinical and laboratory examinations and nephric biopsy. As a result of the treatment, all the patients demonstrated an increase of the level of glomerular filtration, stabilization of protein and lipid metabolism along with the lowering of diurnal proteinuria. Reaferon exerted a beneficial effect on cellular factors of immunity. In some cases, the use of reaferon can be a definite alternative of the conventional treatment methods.

Adolescent↗